Drugs / BL-M24D1
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07255898 | Mar 2026 → Dec 2027 expected | plasma cell myeloma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT07279428 | Jan 2026 → Dec 2027 expected | digestive system neoplasm | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT07232524 | Dec 2025 → Nov 2027 expected | head and neck squamous cell carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT07232420 | Nov 2025 → Dec 2027 expected | non-small cell lung carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-10-22 | Sichuan Biokin Pharmaceutical Co., Ltd. | Regulatory 四川百利天恒药业股份有限公司自愿披露关于注射用BL-M24D1（ADC）治疗复发或难治性血液系统恶性肿瘤和晚期实体瘤获得药物临床试验批准通知书的公告 cninfo.com.cn ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-10-22 | Sichuan Biokin Pharmaceutical Co., Ltd. | 四川百利天恒药业股份有限公司自愿披露关于注射用BL-M24D1（ADC）治疗复发或难治性血液系统恶性肿瘤和晚期实体瘤获得药物临床试验批准通知书的公告 cninfo.com.cn ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BL-M24D1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07255898 ↗ |
| Route | Intravenous | “Administration by intravenous infusion” NCT07232420 ↗ |